Lv11
30 积分 2022-02-25 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
1小时前
待确认
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108
1小时前
求助中
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
28天前
已完结
Multiple myeloma
2个月前
已完结
Multiple myeloma
2个月前
已完结
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
2个月前
已完结
Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T-cell recipients: A real-world study
4个月前
已完结
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
5个月前
已完结
Busulfan Versus Hydroxyurea in the Treatment of Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
5个月前
已关闭
Diagnosis and Treatment of Polycythemia Vera
5个月前
已完结
皖公网安备34019202002308
